The news that Abeona Therapeutics has not received any deficiency letters regarding the clinical efficacy or safety data in their BLA is a strong positive indicator for the company. It suggests that their application is on solid ground from a clinical standpoint, which is critical for gaining regulatory approval. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.